Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2001˜The œAmerican journal of pediatric hematology/oncology

Low Relapse Rate in Children With Acute Lymphoblastic Leukemia After Risk-Directed Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

FTFotini Tzortzatou‐StathopoulouAPAthina PapadopoulouMMMaria Moschovi

Discussion

Loading...

Member takes

Overview

Cohort study demonstrates low relapse and improved event-free survival in children with acute lymphoblastic leukemia, indicating the benefit of risk-directed chemotherapy modifications.

Key Points

  • To evaluate relapse and survival rates in children with acute lymphoblastic leukemia treated with risk-directed therapy and modified chemotherapy protocols.
  • Evaluated 85 consecutive pediatric patients with acute lymphoblastic leukemia (33 good risk, 52 high risk) diagnosed between 1991 and 1996.
  • Protocols were modified post-1993 to reduce toxicity, altering consolidation with lower cytarabine doses and methotrexate omission, while using the BB block of NHL-BFM-90 for high-risk intensification.
  • Bone marrow clearance was evaluated on day 22, and minimal residual disease was monitored using polymerase chain reaction analysis of immunoglobulin heavy-chain gene rearrangements.
  • Relapse occurred in only 2 of 85 children (2.3%), both treated under earlier protocols, while 4 patients with detectable minimal residual disease maintained remission without relapse.
  • The overall cohort achieved a 5-year overall survival of 86% and event-free survival of 83%, with 5-year overall survival of 94% in the good-risk group versus 81% in the high-risk group.
  • Protocol modifications significantly improved 5-year event-free survival in high-risk patients from 65% to 90% (P = 0.04).

Cite This Study

Tzortzatou‐Stathopoulou et al. (2001) studied this question.

synapsesocial.com/papers/6a7204725671bbf00bc2ff75https://doi.org/10.1097/00043426-200112000-00008
View Full Paper
Ask AI
Bookmark
Share